Business Context and Reporting Period
This Form 8-K Current Report was filed by IMPACT BIOMEDICAL INC. on March 11, 2025. The report addresses a corporate governance event under Item 5.02 regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Mr. Chan Heng Fai Ambrose as a Director of the Company, effective March 11, 2025. The filing details Mr. Chan's extensive background, including over 45 years of experience in financial and equity investment, and previous leadership roles at various listed companies such as Alset International Limited, Hapi Metaverse Inc., DSS, Inc., and HWH International Inc.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors related to operations. It explicitly states there are no arrangements or understandings with Mr. Chan regarding his election, no family relationships with existing directors or officers, and no related party transactions involving him.
Investor Verification Checklist
- Verify the effective date of Mr. Chan Heng Fai Ambrose's directorship (March 11, 2025).
- Confirm the absence of related party transactions or compensation arrangements tied to this appointment.
- Review Mr. Chan's prior board service history to assess potential conflicts of interest or strategic alignment.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.